Ovid Therapeutics Inc (OVID) Receives a Buy from Cowen & Co.


In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Ovid Therapeutics Inc (OVID). The company’s shares opened today at $2, close to its 52-week low of $1.72.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.6% and a 50.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Scholar Rock Holding Corp.

Ovid Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $19, representing an 850.0% upside. In a report released today, Ladenburg also maintained a Buy rating on the stock with a $27 price target.

See today’s analyst top recommended stocks >>

Based on Ovid Therapeutics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $12.9 million. In comparison, last year the company had a GAAP net loss of $10.96 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ovid Therapeutics, Inc. is a biopharmaceutical company, which focuses on developing impactful medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts